Skip to main content

Illumina Collaborates With National Cancer Center Japan to Address a Leading Cause of Death in Asia

By: 3BL Media

TruSightâ„¢ Oncology 500 ctDNA panel to be used across a number of Asian countries to develop personalized cancer treatments for Nasopharyngeal Carcinoma

SOURCE: Illumina

DESCRIPTION:

SAN DIEGO, February 4, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) and the National Cancer Center Japan have announced an international joint research project that will use Illumina's high-throughput DNA sequencing to analyse the blood-based genomic profile and clinical information of patients living with Nasopharyngeal Carcinoma. The study will be known as a part of the Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing (A-TRAIN).

One of the main research areas of the project is nasopharyngeal carcinoma, a rare tumor of the head and neck which originates in the nasopharynx and has a higher incidence rate in Asian countries. More than 80 percent of new cases occur in Asia, with Southeast Asian countries accounting for 67 percent of the global burden of all cancer. Nasopharyngeal cancer ranked ninth among incident cancers and eighth among cancer deaths in Southeast Asia.

"We are immensely proud to contribute to this international collaboration and prospective study," said Gretchen Weightman, Head of Global Commercial Strategy and General Manager of Asia Pacific and Japan at Illumina. "Through our joint efforts, we will fuel initiatives that improve health outcomes for people living with nasopharynx cancer and progress the development of personalized treatment, especially those in the Asian community where this carcinoma is most prevalent."

"As nasopharyngeal carcinoma occurs more frequently in Asia and is more difficult to treat, there is a strong need to develop new treatments," said Dr. Kan Yonemori, Principal Investigator at A-TRAIN. "A comprehensive genome profiling panel is a powerful tool to help solve this problem by using blood for genetic analysis. We are grateful for Illumina's support in enabling this important research in numerous Asian countries."

The A-TRAIN study led by the National Cancer Center Hospital Japan is an international joint research project in a number of Asian countries to develop novel treatments based on genomic abnormalities for cancers that are common in Asia. The overall project includes research involving patients with cervical cancer, ovarian cancer, ovarian clear cell carcinoma, nasopharyngeal carcinoma, endometrial cancer and breast cancer, the database will be constructed and analysed by examining genomic abnormalities comprehensively by liquid biopsy, together with clinical information such as treatment details and prognosis.

The study will be conducted as part of an international collaborative study under the Asian clinical TriaLs network for cAncerS (ATLAS) project, which aims to accelerate the implementation of clinical research and to develop personalized treatments. In this study, genomic analysis of blood samples of up to 96 patients with nasopharynx cancer will be analyzed using Illumina's TruSightâ„¢ Oncology 500 ctDNA.

Over the next year, the resulting data will be used by the Japan-led initiative to establish a platform for international collaborative trials with Malaysia, Thailand, the Philippines, Indonesia and Vietnam, which are actively promoting cancer treatment development in the Asian region.

About TruSight Oncology 500

TSO 500 is a Research Use Only comprehensive pan-cancer assay designed to identify 523 known and emerging tumor biomarkers. TSO 500 utilizes both DNA and RNA from tumor samples to identify key variants critical for cancer development and progression, such as small DNA variants, fusions, and splice variants. Based on the content of TSO 500, Illumina will be adding an in vitro diagnostic test to the TruSight Oncology product family. This comprehensive tumor profiling assay will have similar chemistry and analytics to TSO 500. To learn more about TSO 500, click here.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

References
1H. Salehiniya, M. Mohammadian, A Mohammadian-Hafshehani, N. Mahdavifar. Nasopharyngeal Cancer in the World: Epidemiology, Incidence, mortality and Risk Factors. WCRJ 2018;5 (1): e1046

Investors:
Salli Schwartz
858.291.6421
IR@illumina.com

Media:
Dr. Karen Birmingham
EMEA: +44 7500 105665
US: 646.355.2111
kbirmingham@illumina.com

Tweet me: .@illumina is excited to collaborate with @NccriOfficial in Japan to progress personalized treatments for people living with #nasopharynx cancer. The study looked at samples of patients w/nasopharynx cancer analyzed on their TSO 500. Learn more here: https://bit.ly/349oMID

KEYWORDS: illumina, NASDAQ: ILMN, National Cancer Center Japan, TruSightâ„¢ Oncology 500 ctDNA

Japanese woman having a test done on her neck. Hands showing how a nasopharyngeal carcinoma is detected.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.